Enhanced anti-tumor activity of the glycoengineered type II CD20 antibody obinutuzumab (GA101) in combination with chemotherapy in xenograft models of human lymphoma

Por Herting, Frank, Friess, Thomas, Bader, Sabine, Muth, Gunter, Hölzlwimmer, Gabriele, Rieder, Natascha, Umana, Pablo, Klein, Christian
Publicado em 2014

Evaluation of Protein Profiles From Treated Xenograft Tumor Models Identifies an Antibody Panel for Formalin-fixed and Paraffin-embedded (FFPE) Tissue Analysis by Reverse Phase Pro...

Por Bader, Sabine, Zajac, Magdalena, Friess, Thomas, Ruge, Elisabeth, Rieder, Natascha, Gierke, Berthold, Heubach, Yvonne, Thomas, Marlene, Pawlak, Michael
Publicado no Mol Cell Proteomics (2015)

Canine invasive mammary carcinomas as models of human breast cancer. Part 1: natural history and prognostic factors

Por Nguyen, Frédérique, Peña, Laura, Ibisch, Catherine, Loussouarn, Delphine, Gama, Adelina, Rieder, Natascha, Belousov, Anton, Campone, Mario, Abadie, Jérôme
Publicado no Breast Cancer Res Treat (2017)

Antibody mediated CDCP1 degradation as mode of action for cancer targeted therapy

Por Kollmorgen, Gwendlyn, Niederfellner, Gerhard, Lifke, Alexander, Spohn, Gloria J., Rieder, Natascha, Vega Harring, Suzana, Bauss, Frieder, Burtscher, Helmut, Lammers, Reiner, Bossenmaier, Birgit
Publicado no Mol Oncol (2013)

Canine invasive mammary carcinomas as models of human breast cancer. Part 2: immunophenotypes and prognostic significance

Por Abadie, Jérôme, Nguyen, Frédérique, Loussouarn, Delphine, Peña, Laura, Gama, Adelina, Rieder, Natascha, Belousov, Anton, Bemelmans, Ingrid, Jaillardon, Laëtitia, Ibisch, Catherine, Campone, Mario
Publicado no Breast Cancer Res Treat (2017)

A re-engineered immunotoxin shows promising preclinical activity in ovarian cancer

Por Kollmorgen, Gwendlyn, Palme, Klara, Seidl, Annette, Scheiblich, Stefan, Birzele, Fabian, Wilson, Sabine, Clemens, Christian, Voss, Edgar, Kaufmann, Martin, Hirzel, Klaus, Rieder, Natascha, Krippendorff, Ben-Fillippo, Herting, Frank, Niederfellner, Gerhard
Publicado no Sci Rep (2017)

XGFR*, a novel affinity-matured bispecific antibody targeting IGF-1R and EGFR with combined signaling inhibition and enhanced immune activation for the treatment of pancreatic canc...

Por Schanzer, Juergen M., Wartha, Katharina, Moessner, Ekkehard, Hosse, Ralf J., Moser, Samuel, Croasdale, Rebecca, Trochanowska, Halina, Shao, Cuiying, Wang, Peng, Shi, Lei, Weinzierl, Tina, Rieder, Natascha, Bacac, Marina, Ries, Carola H., Kettenberger, Hubert, Schlothauer, Tilman, Friess, Thomas, Umana, Pablo, Klein, Christian
Publicado no MAbs (2016)